A significant reduction in CDK12 mRNA expression was observed in these cell lines relative to HER2-amplified breast cancer cell lines that did not harbour a breakpoint involving CDK12 (Figure 4A; p = 0.0360, t-test). This evidence concerns the gene ERBB2 and breast carcinoma.